MSLE
Income statement / Annual
Last year (2025), Satellos Bioscience Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Satellos Bioscience Inc's net income was -$24.87 M.
See Satellos Bioscience Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$5.09 K
|
$19.99 K
|
$5.28 K
|
$333.98 K
|
$94.05 K
|
$331.24
|
$2.36 K
|
$1.13 K
|
$18.75 K
|
$20.45 K
|
| Gross Profit |
-$5.09 K
|
-$19.99 K
|
-$5.28 K
|
-$333.98 K
|
-$94.05 K
|
-$331.00
|
-$2.36 K
|
-$1.13 K
|
-$18.75 K
|
-$20.45 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.43 M
|
$13.66 M
|
$6.65 M
|
$3.70 M
|
$1.49 M
|
$700.77 K
|
$707.52 K
|
$1.04 M
|
$628.13 K
|
$421.04 K
|
| General & Administrative Expenses |
$7.44 M
|
$5.16 M
|
$4.57 M
|
$3.92 M
|
$1.13 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.44 M
|
$5.16 M
|
$4.57 M
|
$3.92 M
|
$1.13 M
|
$812.49 K
|
$991.04 K
|
$570.91 K
|
$529.03 K
|
$476.54 K
|
| Other Expenses |
$595.00 K
|
$554.63 K
|
$442.49 K
|
-$1.41 M
|
-$1.13 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.46 M
|
$19.38 M
|
$11.66 M
|
$6.21 M
|
$3.71 M
|
$1.51 M
|
$1.70 M
|
$1.61 M
|
$1.16 M
|
$897.58 K
|
| Cost And Expenses |
$26.46 M
|
$19.38 M
|
$11.66 M
|
$6.21 M
|
$94.05 K
|
$1.51 M
|
$1.70 M
|
$1.61 M
|
$1.18 M
|
$918.03 K
|
| Interest Income |
$1.36 M
|
$955.27 K
|
$1.00 M
|
$62.37 K
|
$6.26 K
|
$3.90 K
|
$0.00
|
$305.32
|
$5.12 K
|
$12.37 K
|
| Interest Expense |
$0.00
|
$0.00
|
$133.42 K
|
$0.00
|
$772.80 K
|
$18.09 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.00 K
|
$13.94 K
|
$5.28 K
|
$333.63 K
|
$129.95 K
|
$331.24
|
$2.36 K
|
$1.13 K
|
$18.75 K
|
$20.45 K
|
| EBITDA |
-$26.45 M |
-$19.56 M |
-$11.84 M |
-$10.87 M |
-$11.26 M |
-$1.51 M |
-$1.70 M |
-$1.61 M |
-$1.16 M |
-$897.58 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.76 M
|
-$202.76 K
|
-$321.12 K
|
-$2.13 M
|
-$12.16 M
|
$62.18 K
|
$2.04 K
|
$365.44 K
|
$188.39 K
|
-$192.98 K
|
| Income Before Tax |
-$24.70 M
|
-$19.58 M
|
-$11.98 M
|
-$8.34 M
|
-$12.16 M
|
-$1.45 M
|
-$1.70 M
|
-$1.25 M
|
-$987.52 K
|
-$1.11 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$172.00 K
|
$0.00
|
$0.00
|
$3.68 K
|
-$42.73 K
|
-$212.38 K
|
-$204.20 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$24.87 M
|
-$19.58 M
|
-$11.98 M
|
-$11.21 M
|
-$12.16 M
|
-$1.24 M
|
-$1.49 M
|
-$1.25 M
|
-$987.52 K
|
-$1.11 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-20.4 |
-2.16 |
-1.63 |
-3.78 |
-6.02 |
-16.75 |
-2.93 |
-3.54 |
-1.92 |
-3.58 |
| EPS Diluted |
-20.4 |
-2.16 |
-1.63 |
-3.78 |
-6.02 |
-16.75 |
-2.93 |
-3.54 |
-1.92 |
-3.58 |
| Weighted Average Shares Out |
$1.22 M
|
$9.56 M
|
$7.20 M
|
$2.97 M
|
$2.01 M
|
$73.98 K
|
$510.06 K
|
$351.91 K
|
$351.91 K
|
$351.91 K
|
| Weighted Average Shares Out Diluted |
$1.22 M
|
$9.56 M
|
$7.20 M
|
$2.97 M
|
$2.01 M
|
$73.98 K
|
$510.06 K
|
$351.91 K
|
$351.91 K
|
$351.91 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
